Skip to main content
Top
Published in: Clinical and Experimental Nephrology 12/2021

01-12-2021 | Original article

Combined evaluation of plasma B-type natriuretic peptide and urinary liver-type fatty acid-binding protein/creatinine ratio is related to worsening renal function in patients undergoing elective percutaneous coronary intervention

Authors: Fumiki Yoshihara, Hiroshi Hosoda, Takahito Doi, Morikatsu Yoshida, Kazuo Kitamura, Haruko Yamamoto, Yasuhide Asaumi, Hatsue Ishibashi-Ueda, Masatsugu Kishida, Tetsuya Arisato, Miki Matsuo, Mikiya Miyazato, Satoshi Yasuda

Published in: Clinical and Experimental Nephrology | Issue 12/2021

Login to get access

Abstract

Background

There are few reports on the significance for the combined evaluation of blood humoral factors and urinary biomarkers in terms of worsening renal function (WRF) after coronary angiography (CAG)/percutaneous coronary arterial intervention (PCI).

Method and results

Urinary liver type-fatty acid-binding protein (L-FABP), neutrophil gelatinase associated lipocalin (NGAL), and adrenomedullin (AM) were measured less than 24 h before and 3 h, 6 h, 1 day, and 2 days after CAG/PCI. WRF was defined as a > 20% decrease in the estimated GFR. WRF occurred in seven of 100 patients and the increase in L-FABP/creatinine (Cr) at 1 day after CAG/PCI was significantly higher in the WRF group than in the non-WRF group. Plasma B-type natriuretic peptide (BNP) before CAG/PCI and L-FABP/Cr at 1 day after CAG/PCI were independent predictors for WRF. The areas under the receiver-operating characteristic curves were as follows: 0.760 for BNP before CAG/PCI, 0.731 for L-FABP/Cr at 1 day after CAG/PCI, and 0.892 for BNP and L-FABP/Cr. Urinary AM levels after PCI/CAG were negatively correlated only to serum potassium levels. Gene expressions of AM and AM-receptor were detectable in renal tubule epithelial cells. AM increased intracellular second messenger levels in a dose-dependent manner.

Conclusions

Our results suggest that combined evaluation of plasma BNP and urinary L-FABP/Cr is useful as a predictor of renal dysfunction in CAG/PCI patients.
Literature
1.
go back to reference McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68:1465–73.CrossRef McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68:1465–73.CrossRef
2.
go back to reference Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–8.CrossRef Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–8.CrossRef
3.
go back to reference James MT, Ghali WA, Knudtson ML, Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators, et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation. 2011;123:409–16.CrossRef James MT, Ghali WA, Knudtson ML, Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators, et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation. 2011;123:409–16.CrossRef
4.
go back to reference Reinecke H, Trey T, Matzkies F, et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int. 2003;63:696–701.CrossRef Reinecke H, Trey T, Matzkies F, et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int. 2003;63:696–701.CrossRef
5.
go back to reference Otsuka K, Shimada K, Katayama H, et al. Prognostic significance of renal dysfunction and its change pattern on outcomes in patients with acute coronary syndrome treated with emergent percutaneous coronary intervention. Heart Vessels. 2019;34:735–44.CrossRef Otsuka K, Shimada K, Katayama H, et al. Prognostic significance of renal dysfunction and its change pattern on outcomes in patients with acute coronary syndrome treated with emergent percutaneous coronary intervention. Heart Vessels. 2019;34:735–44.CrossRef
6.
go back to reference Aoki T, Ishii H, Tanaka A, et al. Influence of chronic kidney disease and worsening renal function on clinical outcomes in patients undergoing primary percutaneous coronary intervention. Clin Exp Nephrol. 2019;23:182–8.CrossRef Aoki T, Ishii H, Tanaka A, et al. Influence of chronic kidney disease and worsening renal function on clinical outcomes in patients undergoing primary percutaneous coronary intervention. Clin Exp Nephrol. 2019;23:182–8.CrossRef
7.
go back to reference Ronco C, Stacul F, McCullough PA. Subclinical acute kidney injury (AKI) due to iodine-based contrast media. Eur Radiol. 2013;23:319–23.CrossRef Ronco C, Stacul F, McCullough PA. Subclinical acute kidney injury (AKI) due to iodine-based contrast media. Eur Radiol. 2013;23:319–23.CrossRef
8.
go back to reference Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract. 2014;127:94–100.CrossRef Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract. 2014;127:94–100.CrossRef
9.
go back to reference Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–9.PubMed Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–9.PubMed
10.
go back to reference Maioli M, Toso A, Leoncini M, et al. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation. 2012;125:3099–107.CrossRef Maioli M, Toso A, Leoncini M, et al. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation. 2012;125:3099–107.CrossRef
11.
go back to reference Jarai R, Dangas G, Huber K, et al. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. Circ Cardiovasc Interv. 2012;5:813–20.CrossRef Jarai R, Dangas G, Huber K, et al. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. Circ Cardiovasc Interv. 2012;5:813–20.CrossRef
12.
go back to reference Lin KY, Wu ZY, You ZB, et al. Pre-procedural N-terminal pro-B type natriuretic peptide predicts contrast-induced acute kidney injury and long-term outcome in elderly patients after elective percutaneous coronary intervention. Int Heart J. 2018;59:926–34.CrossRef Lin KY, Wu ZY, You ZB, et al. Pre-procedural N-terminal pro-B type natriuretic peptide predicts contrast-induced acute kidney injury and long-term outcome in elderly patients after elective percutaneous coronary intervention. Int Heart J. 2018;59:926–34.CrossRef
13.
go back to reference Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439–44.CrossRef Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439–44.CrossRef
14.
go back to reference Nozue T, Michishita I, Mizuguchi I. Predictive value of serum cystatin C, β2-microglobulin, and urinary liver-type fatty acid-binding protein on the development of contrast-induced nephropathy. Cardiovasc Interv Ther. 2010;25:85–90.CrossRef Nozue T, Michishita I, Mizuguchi I. Predictive value of serum cystatin C, β2-microglobulin, and urinary liver-type fatty acid-binding protein on the development of contrast-induced nephropathy. Cardiovasc Interv Ther. 2010;25:85–90.CrossRef
15.
go back to reference Fujita D, Takahashi M, Doi K, et al. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease. Heart Vessels. 2015;30:296–303.CrossRef Fujita D, Takahashi M, Doi K, et al. Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease. Heart Vessels. 2015;30:296–303.CrossRef
16.
go back to reference Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22:2089–95.CrossRef Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22:2089–95.CrossRef
17.
go back to reference Ling W, Zhaohui N, Ben H, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108:c176-181.CrossRef Ling W, Zhaohui N, Ben H, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108:c176-181.CrossRef
18.
go back to reference Naruse H, Ishii J, Takahashi H, et al. Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units. Crit Care. 2018;22:197.CrossRef Naruse H, Ishii J, Takahashi H, et al. Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units. Crit Care. 2018;22:197.CrossRef
19.
go back to reference De Berardinis B, Gaggin HK, Magrini L, Global Research on Acute Conditions Team (GREAT), et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clin Chem Lab Med. 2015;53:613–21.CrossRef De Berardinis B, Gaggin HK, Magrini L, Global Research on Acute Conditions Team (GREAT), et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clin Chem Lab Med. 2015;53:613–21.CrossRef
20.
go back to reference Palazzuoli A, Beltrami M, Pellegrini M, et al. Natriuretic peptides and NGAL in heart failure: does a link exist? Clin Chim Acta. 2012;413:1832–8.CrossRef Palazzuoli A, Beltrami M, Pellegrini M, et al. Natriuretic peptides and NGAL in heart failure: does a link exist? Clin Chim Acta. 2012;413:1832–8.CrossRef
21.
go back to reference Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18:2894–902.CrossRef Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18:2894–902.CrossRef
22.
go back to reference Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15:3073–82.CrossRef Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15:3073–82.CrossRef
23.
go back to reference Zhu T, Yang J, Liu X, et al. Hypoxia-inducible adrenomedullin ameliorates the epithelial-to-mesenchymal transition in human proximal tubular epithelial cells. Mol Med Rep. 2015;11:3760–6.CrossRef Zhu T, Yang J, Liu X, et al. Hypoxia-inducible adrenomedullin ameliorates the epithelial-to-mesenchymal transition in human proximal tubular epithelial cells. Mol Med Rep. 2015;11:3760–6.CrossRef
24.
go back to reference Uetake R, Sakurai T, Kamiyoshi A, et al. Adrenomedullin-RAMP2 system suppresses ER stress-induced tubule cell death and is involved in kidney protection. PLoS One. 2014;9:e87667.CrossRef Uetake R, Sakurai T, Kamiyoshi A, et al. Adrenomedullin-RAMP2 system suppresses ER stress-induced tubule cell death and is involved in kidney protection. PLoS One. 2014;9:e87667.CrossRef
25.
go back to reference Oyar EÖ, Kiriş I, Gülmen S, et al. The protective effect of adrenomedullin on renal injury, in a model of abdominal aorta cross-clamping. Thorac Cardiovasc Surg. 2012;60:5–10.CrossRef Oyar EÖ, Kiriş I, Gülmen S, et al. The protective effect of adrenomedullin on renal injury, in a model of abdominal aorta cross-clamping. Thorac Cardiovasc Surg. 2012;60:5–10.CrossRef
26.
go back to reference Inal S, Koc E, Ulusal-Okyay G, et al. Protective effect of adrenomedullin on contrast induced nephropathy in rats. Nefrologia. 2014;34:724–31.PubMed Inal S, Koc E, Ulusal-Okyay G, et al. Protective effect of adrenomedullin on contrast induced nephropathy in rats. Nefrologia. 2014;34:724–31.PubMed
27.
go back to reference Matsuo S, Imai E, Horio M, Collaborators developing the Japanese equation for estimated GFR, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, Collaborators developing the Japanese equation for estimated GFR, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
28.
go back to reference Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43:1551–61.CrossRef Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43:1551–61.CrossRef
29.
go back to reference Hobson CE, Yavas S, Segal MS, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009;119:2444–53.CrossRef Hobson CE, Yavas S, Segal MS, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009;119:2444–53.CrossRef
30.
go back to reference Kamijo-Ikemori A, Hashimoto N, Sugaya T, et al. Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events. Int J Nephrol Renovasc Dis. 2015;8:91–9.CrossRef Kamijo-Ikemori A, Hashimoto N, Sugaya T, et al. Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events. Int J Nephrol Renovasc Dis. 2015;8:91–9.CrossRef
31.
go back to reference Asada T, Isshiki R, Hayase N, et al. Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein. Sci Rep. 2016;6:33077.CrossRef Asada T, Isshiki R, Hayase N, et al. Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein. Sci Rep. 2016;6:33077.CrossRef
32.
go back to reference Seeliger E, Sendeski M, Rihal CS, et al. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007–15.CrossRef Seeliger E, Sendeski M, Rihal CS, et al. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007–15.CrossRef
33.
go back to reference Nishikimi T, Horio T, Kohmoto Y, et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens. 2001;19:765–73.CrossRef Nishikimi T, Horio T, Kohmoto Y, et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens. 2001;19:765–73.CrossRef
34.
go back to reference Kubo A, Iwano M, Minamino N, et al. Measurement of plasma and urinary adrenomedullin in patients with IgA nephropathy. Nephron. 1998;78:389–94.CrossRef Kubo A, Iwano M, Minamino N, et al. Measurement of plasma and urinary adrenomedullin in patients with IgA nephropathy. Nephron. 1998;78:389–94.CrossRef
35.
go back to reference Balat A, Cekmen M, Yürekli M, et al. Adrenomedullin and nitrite levels in children with Bartter syndrome. Pediatr Nephrol. 2000;15:266–70.CrossRef Balat A, Cekmen M, Yürekli M, et al. Adrenomedullin and nitrite levels in children with Bartter syndrome. Pediatr Nephrol. 2000;15:266–70.CrossRef
36.
go back to reference Sendeski MM, Persson AB, Liu ZZ, et al. Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta. Am J Physiol Renal Physiol. 2012;303:F1592-1598.CrossRef Sendeski MM, Persson AB, Liu ZZ, et al. Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta. Am J Physiol Renal Physiol. 2012;303:F1592-1598.CrossRef
Metadata
Title
Combined evaluation of plasma B-type natriuretic peptide and urinary liver-type fatty acid-binding protein/creatinine ratio is related to worsening renal function in patients undergoing elective percutaneous coronary intervention
Authors
Fumiki Yoshihara
Hiroshi Hosoda
Takahito Doi
Morikatsu Yoshida
Kazuo Kitamura
Haruko Yamamoto
Yasuhide Asaumi
Hatsue Ishibashi-Ueda
Masatsugu Kishida
Tetsuya Arisato
Miki Matsuo
Mikiya Miyazato
Satoshi Yasuda
Publication date
01-12-2021
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 12/2021
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-021-02113-9

Other articles of this Issue 12/2021

Clinical and Experimental Nephrology 12/2021 Go to the issue

Acknowledgment

List of referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine